Clik here to view.
Systemic Therapy for Non-Melanoma Skin Cancer
David G. Pfister, MD, discussed non-melanoatous skin cancers including squamous cell, basal cell, dermatofibrosarcoma protuberans and merkel cell at the HemOnc Today Melanoma and Cutaneous Malignancies...
View ArticleClik here to view.
Matastasectomy: Does it make sense in the setting of effective systemic therapy?
Vernon K. Sondak, MD, discussed the who, why and when of surgery for metastatic melanoma at the HemOnc Today Melanoma and Cutaneous Malignancies symposium. Sondak explained that improvements in imaging...
View ArticleClik here to view.
New Melanoma Syndromes from the Genetic Perspective
Hensin Tsao, MD, PhD, discussed some new insights into familial melanoma syndromes and explained that about 10% of melanomas are familial, while the rest are sporadic at the HemOnc Today Melanoma and...
View ArticleClik here to view.
PD1 Antibodies
Jeffrey Weber, MD, PhD, explained PD-1's role in T cell activation at the HemOnc Today Melanoma and Cutaneous Malignancies symposium. Weber explained that PD-1 is a member of the CD28 family involved...
View ArticleClik here to view.
B-Raf and MEK: Current Status of Combination Therapy
Jeffrey Weber, MD, PhD, discussed the number of combination drugs using B-Raf and MECk for the treatment of melanoma. Weber explained a Phase I/II clinical trial of 400 participants looking at...
View ArticleClik here to view.
IL-2 Single Agent and Combinations
Michael K.K. Wong, MD, PhD, FRCPC, discussed IL-2 being a viable first option in selected patients with metastatic melanoma and that it is a viable combination agent with other immunoRx and targeted...
View ArticleClik here to view.
Highlights from the HemOnc Today Melanoma meeting
NEW YORK - Sanjiv S. Agarwala, MD, highlights the topics covered at the HemOnc Today Melanoma symposium including surgical treatments, therapy, metastatic disease and even non-melanoma cutaneous...
View ArticleClik here to view.
Skin Cancer in Young People
Mayo Clinic dermatologist Jerry Brewer, MD, discusses the rise of melanoma in young people and explains why Mayo created a public service message.
View ArticleClik here to view.
Tighter Rules on Indoor Tanning
Professor Mary Maloney, MD, is advocating for stricter federal regulations on tanning beds.
View ArticleClik here to view.
Melanoma Advances in Targeted Therapy
Jeff Infante, MD, director of the Drug Development Unit at Sarah Cannon Research Institute and Medical Oncologist at Tennessee Oncology, shares the latest information.
View ArticleClik here to view.
3 Important Risk Factors for Melanoma
Anokhi Jambusaria, MD, dermatologist at Mayo Clinic in Florida, talks about the standard treatment for melanoma. She also discusses the three most important risk factors.
View ArticleClik here to view.
Physicians: Avoid Tanning Beds
Richard W. Joseph, MD, medical oncologist, and Anokhi Jambusaria, MD, dermatologist, both from Mayo Clinic in Florida talk about why one should NEVER use tanning beds. "Pale is the new tan," Jamusaria...
View ArticleClik here to view.
Exams Catching Melanoma Earlier
Studies show diligence pays off, in particular when it comes to melanoma, the most lethal form of skin cancer. Patients who had at least one skin exam were 37% less likely to have invasive disease if...
View ArticleClik here to view.
T-VEC yielded encouraging response rates and survival outcomes in unresected...
Robert Andtbacka, MD, CM, a surgical oncologist at the Huntsman Cancer Institute in Salt Lake City, Utah, discussed encouraging results for talimogene laherparepvec (T-VEC, Amgen), an oncolytic...
View ArticleClik here to view.
Young Women at High Risk for Melanoma
Melanoma cases are on the rise, with young women being prime targets fro this dangerous cancer. “The melanoma skin cancer has the greatest ability to spread to other organs and other parts of the body...
View ArticleClik here to view.
Diabetes Drugs as Possible Melanoma Treatment
Can diabetes drugs help kill therapy-resistant, advanced melanoma? New findings from The Wistar Institute's Melanoma are presented.
View ArticleClik here to view.
Addition of lapatnib linked to improved response, not survival outcomes in...
Barbara Burtness, MD, a medical oncologist at Fox Chase Cancer Center who specializes in head and neck cancers and a HemOnc Today Editorial Board member, discusses the TRIO-013 (LOGiC) trial of...
View ArticleClik here to view.
BRAF inhibitors exhibited high response rates, limited impact on survival
PARIS –Alexander M.M. Eggermont, MD, PhD, director of the Cancer Institute Gustave Roussy in Villejuif, France, highlights the high response rates that have been associated with BRAF inhibitors such...
View ArticleClik here to view.
Advances enacted in melanoma drug development could redefine treatment
PARIS –Alexander M.M. Eggermont, MD, PhD, director of the Cancer Institute Gustave Roussy in Villejuif, France, discusses how the landscape of metastatic melanoma has changed since the approval of...
View ArticleClik here to view.
Multidisciplinary Approach to Treating Melanoma
UW Health surgical oncologist Heather Neuman, MD, discusses the multidisciplinary nature of the organization's approach to melanoma treatment.
View Article
